| Prev Close | 179.33 |
| Open | 183.82 |
| Day Low/High | 177.17 / 186.50 |
| 52 Wk Low/High | 6.26 / 189.40 |
| Volume | 2.11M |
Novavax, Inc. (NVAX)
185.35
6.00
3.40
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 74.09B |
| Market Cap | 13.63B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
CureVac Is Down But Not Out: Here's How to Trade It
CVAC is now working on a 'next generation' COVID-19 vaccine candidate with GlaxoSmithKline.
If a COVID Vaccine Becomes Seasonal, Watch Novavax: Here's 2 Ways to Trade It
I prefer the bear put spread over the covered equity play due to the decreased risk to principal, despite the capped potential for profit.
Moderna's Charts Are Bullish and Pointed Higher
Here's the area where I would like to go long MRNA.
We Are a Foolish People, Colonial Pipeline, Cryptocurrencies, Job Numbers
Beyond refined fuels, what else is susceptible to sophisticated criminal or terrorist activity? The entire grid? Clean water?
ARKK Under Pressure, Peloton, Vaccine Moral Dilemma, Charting the Nasdaq
The fund is at a key spot technically, and there is real fear that if this spot cracks, what looks like a stretch of rough rapids could become a waterfall.
Novavax Is Poised for Renewal After Its Correction
Here's our updated analysis and trading strategy.
I'm Not Bailing on Johnson & Johnson Now
Don't forget, this is a very large company with a lot more than the vaccine going on.
The XBI SPDR S&P Biotech ETF Reaches a Critical Juncture
XBI has shown a steep decline from the middle of February.
Deceptive Thursday, Rotational Roundabout, Biden Bits, Disparate Fed Data
Plus, the efficacy rate of the still-pending Novavax Covid-19 vaccine against variants of the virus give reason for pause.
Biden Bits, Vaccine Vanguard, Unmasking Folly, Minerd Musings, Ives Inklings
Among other things, the president works to align Democratic senators to support his massive Covid relief bill.
Unconvincing Rally, U.S. Dollar, Friday's 800-Pound Gorilla, Playing Pepper
Everything came up roses Monday -- except for what matters most, broad participation.
What's Up at the Fed? Supply & Demand, 12 Trading Notes, Microsoft Conference
Should we care about Australia's central bank taking overtly aggressive action to reign in the long end of their yield curve? Yes, we should.
This Is Why He Is The Smartest Trader in the World
* He shoots, he scores - with NVAX (+65% or +$87/share) today Several subscribers have expressed disinterest and even snarkiness in The Smartest Trader in the World's positions -- others like to see his book on almost a daily basis. I posted this up...
I've Come Around to Thinking of Boeing as an Investment
I think BA returns to normal as we do, as the airlines do... but with the defense contracting business as a foundation to rely upon.
The Meaning of Biden, Overbought Markets? Fun With Charts
Can corporate America grow sales for the fourth quarter? Then answer a question with a question.
A Healthy Dose of Vaccine and Pharmaceutical Plays
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Jim Cramer: The Seven Deadly Stock Sins (as Seen on Twitter)
Penny stocks are for suckers, and six other rules for better investing -- and tuning out the tweet noise.
Emergent BioSolutions Could See Further Upside Gains
Most of the indicators are still bullish in this name, although some profit-taking may be occurring.
Trade Cautiously With Sorrento Therapeutics
Short-term traders may want to nail down profits and be careful in their trading strategy with this name.
Jim Cramer: What Happens in a Bull Market Is That Stocks Move Up on Nothing
Isaac Newton's first lesson: An object in motion stays in motion with the same speed and in the same direction unless acted upon by an unbalanced force.
The Relevance of the Russell 2000
The performance of IWM is telling you that all is not well in the overall U.S. economy.
Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
Jim Cramer: How Do You Refute These Market Gains?
This is pretty much exactly what you get when you have so much positive research.
These 3 Biotechs Have Decent Values
One would need to use covered calls to initiate positions that provide a solid amount of downside protection.
Novavax and Its $1.6 Billion Award Just Got My Attention
The smallish clinical-stage vaccine company looks like a trade, not an investment, and might be approached as an option play.
Novavax Could Surprise on the Upside - No Bearish Divergences Yet
Let's review the charts and indicators.
Count Me a Covid-19 Skeptic, Including When It Comes to a Vaccine
The extent of the measures taken to combat the virus seem to be an overreaction, and no one should count on a vaccine being a magic bullet.
Arcturus Therapeutics Has a Candidate for a Covid-19 Vaccine
When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.
